NASDAQ · Biotechnology

Terns Pharmaceuticals, Inc. (TERN) Stock

$52.95 -0.04% NASDAQ: TERN Healthcare

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.

Valuation

MetricValue
Price$52.95
Market Cap$4.77B
P/E Ratio-51.41
P/B Ratio4.74
P/S Ratio0.00
EPS (TTM)$-1.03
52-Week High$53.19
52-Week Low$2.65
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-9.53%
ROA-9.37%
ROCE-10.93%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio64.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$0$0$0$0
Operating Profit$-50.0M$-62.0M$-103.0M$-102.0M$-110.0M
Net Profit$-50.0M$-60.0M$-90.0M$-89.0M$-96.0M
EPS$-1.98$-1.67$-1.27$-1.12$-1.03
Op Margin-4986.0%————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$168.0M$287.0M$269.0M$364.0M$1.0B
Total Liabilities$8.0M$10.0M$13.0M$18.0M$19.0M
Cash$48.0M$143.0M$80.0M$161.0M$525.0M
Borrowings$0$1.0M$1.0M$1.0M$1.0M

Latest News

Newmont's Q2 Earnings Beat Estimates, Sales Lag on Lower Volumes Zacks · Jul 24, 2026 FCX's Q2 Earnings and Revenues Top Estimates on Higher Metal Prices Zacks · Jul 23, 2026 Bunge Ready to Report Q2 Earnings: What's in Store for the Stock? Zacks · Jul 23, 2026 Vale Gears Up to Report Q2 Earnings: Here's What to Expect Zacks · Jul 23, 2026 Ternium (TX) Is Attractively Priced Despite Fast-paced Momentum Zacks · Jul 23, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-42.0M$-49.0M$-67.0M$-70.0M$-82.0M
Investing Cash Flow$-120.0M$-23.0M$-38.0M$-12.0M$-298.0M
Financing Cash Flow$11.0M$0$0$2.0M$0
Net Cash Flow$-27.0M$96.0M$-63.0M$82.0M$363.0M
Free Cash Flow$-42.0M$-49.0M$-67.0M$-70.0M$-82.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-1.72%
Quick Ratio62.41
Interest Coverage—
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AMLX $22.82 -5.66% -8.69 $2.54B 0.00%
ELVN $60.46 +0.32% -19.91 $4.32B 0.00%
IMTX $8.24 -4.52% -4.98 $1.10B 0.00%
INBXInhibrx Biosciences Inc. $81.54 -0.01% -9.72 $1.20B 0.00%
NKTR $70.68 -0.13% -6.95 $1.38B 0.00%

About Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. As of May 4, 2026, Terns Pharmaceuticals, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.

Terns Pharmaceuticals, Inc. (TERN) stock trades at $52.95 with a market capitalization of $4.77B. The stock is valued at a price-to-earnings (P/E) ratio of -51.41, price-to-book of 4.74, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.65 and $53.19, and currently trades at its 52-week high.

On profitability, Terns Pharmaceuticals, Inc. generates a return on equity (ROE) of -9.53%, return on capital employed of -10.93%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides